Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers

NCT03291899 is registered in ClinicalTrials.gov with King Faisal Specialist Hospital & Research Center as lead sponsor.

NCT NCT03291899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03291899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers
Lead sponsor
King Faisal Specialist Hospital & Research Center
Phase
Phase 2
Overall status
Terminated
Start date
January 3, 2017
Completion date
February 9, 2023
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer